Henry King Ransom Endowed Professor of Surgery, Internal Medicine, and Nutritional Sciences
University of Michigan
Ann Arbor, Michigan, United States
Dr. Randy Seeley is the Henry K. Ransom Endowed Professor of Surgery at the University of Michigan School of Medicine. He also serves as the director of the NIH-funded Michigan Nutrition Obesity Research Center (MNORC). His scientific work has focused on the gut-brian axis and its role in regulating energy balance and metabolism, emphasizing new treatment strategies for obesity and diabetes. He has published over 400 peer-reviewed articles that have been cited more than 44,000 times and Dr. Seeley has a Scopus h-index of 103. Dr. Seeley has received numerous awards including the 2009 Outstanding Scientific Achievement Award from the American Diabetes Association.
New Insights Into the Far-Reaching Effects of Obesity Medicines
Tuesday, June 3, 2025
10:00 AM – 11:30 AM ET
Disclosure(s): Amgen: Advisory Committee/Board Member (Ongoing); Grant/Research Support (Ongoing)
AstraZeneca: Consultant (Ongoing); Grant/Research Support (Ongoing)
Congruence: Grant/Research Support (Ongoing)
Coro Bio: Advisory Committee/Board Member (Ongoing); Ownership Interest (Ongoing)
Crinetics: Advisory Committee/Board Member (Ongoing)
Eli Lilly: Consultant (Ongoing); Grant/Research Support (Ongoing)
Fractyl: Advisory Committee/Board Member (Ongoing); Grant/Research Support (Ongoing)
Glyscend: Grant/Research Support (Ongoing)
Metsera: Consultant (Ongoing)
Novo Nordisk: Consultant (Terminated, January 1, 2024); Grant/Research Support (Terminated, January 1, 2024)
Nuanced Health: Advisory Committee/Board Member (Ongoing); Ownership Interest (Ongoing)
Rewind: Ownership Interest (Ongoing)
Tuesday, June 3, 2025
10:05 AM – 10:25 AM ET
Disclosure(s): Amgen: Advisory Committee/Board Member (Ongoing); Grant/Research Support (Ongoing)
AstraZeneca: Consultant (Ongoing); Grant/Research Support (Ongoing)
Congruence: Grant/Research Support (Ongoing)
Coro Bio: Advisory Committee/Board Member (Ongoing); Ownership Interest (Ongoing)
Crinetics: Advisory Committee/Board Member (Ongoing)
Eli Lilly: Consultant (Ongoing); Grant/Research Support (Ongoing)
Fractyl: Advisory Committee/Board Member (Ongoing); Grant/Research Support (Ongoing)
Glyscend: Grant/Research Support (Ongoing)
Metsera: Consultant (Ongoing)
Novo Nordisk: Consultant (Terminated, January 1, 2024); Grant/Research Support (Terminated, January 1, 2024)
Nuanced Health: Advisory Committee/Board Member (Ongoing); Ownership Interest (Ongoing)
Rewind: Ownership Interest (Ongoing)
Panel Discussion - New Insights Into the Far-Reaching Effects of Obesity Medicines
Tuesday, June 3, 2025
11:05 AM – 11:30 AM ET
Disclosure(s): Amgen: Advisory Committee/Board Member (Ongoing); Grant/Research Support (Ongoing)
AstraZeneca: Consultant (Ongoing); Grant/Research Support (Ongoing)
Congruence: Grant/Research Support (Ongoing)
Coro Bio: Advisory Committee/Board Member (Ongoing); Ownership Interest (Ongoing)
Crinetics: Advisory Committee/Board Member (Ongoing)
Eli Lilly: Consultant (Ongoing); Grant/Research Support (Ongoing)
Fractyl: Advisory Committee/Board Member (Ongoing); Grant/Research Support (Ongoing)
Glyscend: Grant/Research Support (Ongoing)
Metsera: Consultant (Ongoing)
Novo Nordisk: Consultant (Terminated, January 1, 2024); Grant/Research Support (Terminated, January 1, 2024)
Nuanced Health: Advisory Committee/Board Member (Ongoing); Ownership Interest (Ongoing)
Rewind: Ownership Interest (Ongoing)